Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Outcome of allo-SCT for chronic myelomonocytic leukemia

Bone Marrow Transplantation volume 43, pages 659–661 (2009)Cite this article

Chronic myelomonocytic leukemia (CMML) is a rare heterogeneous malignancy with an annual incidence of 13:100 000 occurring predominantly >65 years of age. The phenotype varies from myelodysplastic to myeloproliferative features, and the clinical course is heterogeneous.1 Treatment strategies are expanding because of new compounds, for example, lenalidomide2 or intensive chemotherapy for advanced stages,3 and increasing numbers of patients receive allogeneic haematopoietic SCT from related/unrelated donors facilitated by reduced intensity conditioning (RIC).4 The design of guidelines based on the individual risk profiles is difficult in CMML,5 as its rare heterogenous presentation hampers the evaluation of larger samples. To contribute to insights in the outcome of SCT in this rare disorder, we retrospectively analyzed 12 consecutive CMML patients receiving 13 allogeneic SCT at the University of Hamburg, Germany, from January 2003 to June 2007.

All 12 patients gave informed consent. Some patients were included in a previous study.6 One patient (no. 1) received two allo-SCTs from two different unrelated donors. Eleven patients had unrelated donors (six HLA matched, five mismatched in the HLA-DQB1-alleles), and two received SCT from HLA-identical siblings. All 13 transplants were performed with PBSCs (mean dose 7.65 × 106 CD34+/kg; range 3.9–11.34). The CMV status was the same in 12 donor/recipient pairs (Table 1).

Table 1 Characteristics of 12 patients with CMML receiving 13 allo-SCTs (patient no. 1 received two allo-SCTs)
Full size table

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Aul C, Giagounidis A, Germing U, Ganser A . Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81: 485–497.

    Article  CAS  Google Scholar 

  2. Platzbecker U, Mohr B, von Bonin M, Schetelig J, Ehninger G, Bornhauser M . Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007; 21: 2384–2385.

    Article  CAS  Google Scholar 

  3. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004; 83: 498–503.

    Article  CAS  Google Scholar 

  4. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95: 1188–1194.

    CAS  PubMed  Google Scholar 

  5. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Bienzen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67–73.

    Article  Google Scholar 

  6. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336–342.

    Article  CAS  Google Scholar 

  7. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099.

    Article  CAS  Google Scholar 

  8. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006; 37: 1003–1008.

    Article  CAS  Google Scholar 

  9. Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11: 713–720.

    Article  Google Scholar 

  10. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246–255.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interdisciplinary Clinic for Stem Cell Transplantation, University of Hamburg, Hamburg, Germany

    S Ocheni, N Kröger, T Zabelina, A R Zander & U Bacher

  2. Department of Haematology and Immunology, University of Nigeria, Nsukka, Enugu Campus, Nigeria

    S Ocheni

Authors
  1. S Ocheni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Zabelina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A R Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U Bacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U Bacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocheni, S., Kröger, N., Zabelina, T. et al. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 43, 659–661 (2009). https://doi.org/10.1038/bmt.2008.366

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.366

This article is cited by

Search

Advanced search

Quick links